Chemed/$CHE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Chemed
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Ticker
$CHE
Sector
Primary listing
NYSE
Employees
15,695
Headquarters
Website
Chemed Metrics
BasicAdvanced
$6.6B
23.51
$19.48
0.46
$2.10
0.52%
Price and volume
Market cap
$6.6B
Beta
0.46
52-week high
$623.61
52-week low
$408.42
Average daily volume
183K
Dividend rate
$2.10
Financial strength
Current ratio
1.862
Quick ratio
1.648
Long term debt to equity
8.499
Total debt to equity
12.145
Dividend payout ratio (TTM)
10.17%
Interest coverage (TTM)
220.65%
Profitability
EBITDA (TTM)
434.165
Gross margin (TTM)
33.65%
Net profit margin (TTM)
11.56%
Operating margin (TTM)
14.92%
Effective tax rate (TTM)
25.16%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
13.56%
Return on equity (TTM)
24.14%
Valuation
Price to earnings (TTM)
23.512
Price to revenue (TTM)
2.693
Price to book
5.55
Price to tangible book (TTM)
15.04
Price to free cash flow (TTM)
18.213
Free cash flow yield (TTM)
5.49%
Free cash flow per share (TTM)
25.14
Dividend yield (TTM)
0.46%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
7.55%
Earnings per share change (TTM)
-1.23%
3-year revenue growth (CAGR)
5.46%
10-year revenue growth (CAGR)
5.32%
3-year earnings per share growth (CAGR)
2.67%
10-year earnings per share growth (CAGR)
12.38%
3-year dividend per share growth (CAGR)
11.57%
10-year dividend per share growth (CAGR)
8.56%
What the Analysts think about Chemed
Analyst ratings (Buy, Hold, Sell) for Chemed stock.
Bulls say / Bears say
Net patient revenue for the VITAS segment increased 15.1% to $407.4 million in Q1 2025, driven by a 13.1% rise in average daily census and higher Medicare reimbursement rates, highlighting the continued strength of Chemed's hospice operations (Reuters)
Chemed ended Q2 2025 with $249.9 million in cash and no debt, enhancing its financial flexibility and ability to pursue investments or return capital to shareholders (Reuters)
Q1 2025 adjusted diluted EPS of $5.63 topped the consensus estimate of $5.55, demonstrating solid cost controls and resilient margins despite ongoing macroeconomic uncertainty (Reuters)
Roto-Rooter's adjusted EBITDA dropped 18.7% year-over-year to $48.6 million in Q2 2025, with margins decreasing by 517 basis points, signaling persistent operational challenges in the plumbing division (Reuters)
Adjusted diluted EPS of $4.27 in Q2 2025 fell short of analyst estimates of $4.98 and declined 21.9% year-over-year, exposing considerable earnings pressure across the company (Reuters)
The announced departure of Nicholas M. Westfall as Executive Vice President and VITAS CEO creates leadership uncertainty in Chemed's core hospice business, potentially disrupting strategic direction (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Chemed Financial Performance
Revenues and expenses
Chemed Earnings Performance
Company profitability
Chemed News
AllArticlesVideos
Chemed Corporation Board of Directors Authorizes an Additional $300 Million for Stock Repurchase and Declares Quarterly Dividend of 60 Cents
Business Wire1 month ago
Chemed Reports Second-Quarter 2025 Results and Announces Executive Management Departure
Business Wire1 month ago
Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Chemed stock?
Chemed (CHE) has a market cap of $6.6B as of September 13, 2025.
What is the P/E ratio for Chemed stock?
The price to earnings (P/E) ratio for Chemed (CHE) stock is 23.51 as of September 13, 2025.
Does Chemed stock pay dividends?
Yes, the Chemed (CHE) stock pays dividends to shareholders. As of September 13, 2025, the dividend rate is $2.1 and the yield is 0.52%. Chemed has a payout ratio of 10.17% on a trailing twelve-month basis.
When is the next Chemed dividend payment date?
The next Chemed (CHE) dividend payment date is unconfirmed.
What is the beta indicator for Chemed?
Chemed (CHE) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.